Medtecs International Beheer

Beheer criteriumcontroles 2/4

De CEO Medtecs International is William Yang, benoemd in May2018, heeft een ambtstermijn van 6.5 jaar. bezit rechtstreeks 0.55% van de aandelen van het bedrijf, ter waarde SGD 396.00K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.7 jaar en 5.9 jaar.

Belangrijke informatie

William Yang

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	6.5yrs
Eigendom CEO	0.6%
Management gemiddelde ambtstermijn	3.7yrs
Gemiddelde ambtstermijn bestuur	5.9yrs

Recente managementupdates

Recent updates

CEO

William Yang (41 yo)

6.5yrs

Tenure

Mr. Weiyuan Yang, also known as William, has been General Manager of Medtecs Taiwan Corporation since 2010. Mr. Yang has been Chief Executive Officer of Medtecs International Corporation Limited since May...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ker-Cheng Yang	Executive Chairman	27yrs	geen gegevens	7.2% SGD 5.2m
Weiyuan Yang	CEO & Deputy Chairman	6.5yrs	geen gegevens	0.55% SGD 396.0k
Yi-Ching Lin	Chief Financial Officer	2.9yrs	geen gegevens	geen gegevens
Chien Yang Wan	General Counsel	3.7yrs	geen gegevens	geen gegevens
Abdul Jabbar Bin Karam Din	Company Secretary	no data	geen gegevens	geen gegevens

3.7yrs

Gemiddelde duur

Ervaren management: Het managementteam van 546 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ker-Cheng Yang	Executive Chairman	27yrs	geen gegevens	7.2% SGD 5.2m
Weiyuan Yang	CEO & Deputy Chairman	11.2yrs	geen gegevens	0.55% SGD 396.0k
Chien-Chung Nieh	Independent Director	no data	geen gegevens	geen gegevens
Mui Choo Low	Lead Independent Non-Executive Director	less than a year	geen gegevens	geen gegevens
Zhao Yuhong	Independent Non-Executive Director	less than a year	geen gegevens	geen gegevens

5.9yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 546 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.9 jaar).

Medtecs International Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Medtecs International Corporation Limited Changes to the Composition of the Board of Directors and Board Committees

Medtecs International Corporation Limited, Annual General Meeting, Apr 30, 2024

Medtecs International Corporation Limited, Annual General Meeting, Jun 30, 2023

Insufficient new directors

Insufficient new directors

Medtecs International Corporation Limited, Annual General Meeting, Apr 29, 2022

Recent updates

First half 2024 earnings released: US$0.007 loss per share (vs US$0.01 loss in 1H 2023)

Medtecs International Corporation Limited Changes to the Composition of the Board of Directors and Board Committees

Medtecs International Corporation Limited, Annual General Meeting, Apr 30, 2024

Full year 2023 earnings released

First half 2023 earnings released: US$0.01 loss per share (vs US$0.007 loss in 1H 2022)

New major risk - Revenue and earnings growth

Full year 2022 earnings released: US$0.052 loss per share (vs US$0.032 profit in FY 2021)

Medtecs International Corporation Limited, Annual General Meeting, Jun 30, 2023

Full year 2022 earnings released

Medtecs International Corporation Limited Provides Group Earnings Guidance for the Second Half of 2022 and for the Financial Year Ended 31 December 2022

Medtecs International Corporation Limited to Report Fiscal Year 2022 Results on Mar 01, 2023

Insufficient new directors

First half 2022 earnings released: EPS: US$0 (vs US$0.035 in 1H 2021)

Now 20% undervalued after recent price drop

Medtecs International Corporation Limited Provides Earnings Guidance for First Half of 2022

Medtecs International Corporation Limited Approves Final Dividend for the Financial Year Ended 31 December 2021, Payable on or Around 30 June 2022

Now 21% undervalued after recent price drop

Medtecs International Corporation Limited Declares Tax Exempt One-Tier Final Dividend for the Financial Year Ended 31 December 2021

Price target decreased to S$0.92

Insufficient new directors

Full year 2021 earnings released: EPS: US$0.032 (vs US$0.24 in FY 2020)

Medtecs International Corporation Limited, Annual General Meeting, Apr 29, 2022

Medtecs International Corporation Limited Recommends One-Tier, Tax Exempt Final Dividend for the Year Ended 31 December 2021

Full year 2021 earnings: Revenues miss analyst expectations

Insufficient new directors

Chief Financial Officer Wilfrido Candelaria Rodriguez has left the company

Medtecs International Corporation Limited Provides Earnings Guidance for the Fourth Quarter, Second Half and Full Year of Financial Year Ending 31 December 2021

Medtecs International Corporation Limited Launches A Line-Up of Face Masks for Children in Six Vibrant Colors on Amazon

CEO & Deputy Chairman recently bought S$287k worth of stock

CEO & Deputy Chairman recently bought S$420k worth of stock

Investor sentiment improved over the past week

CEO & Deputy Chairman recently bought S$479k worth of stock

Price target decreased to S$0.92

Consensus forecasts updated

Medtecs International Corporation Limited Provides Revenue Guidance for the Second Quarter Ending 30 June 2021

Upcoming dividend of US$0.042 per share

Independent Director has left the company

Medtecs International Corporation Limited Approves Tax Exempt One-Tier Final Dividend for the Year Ended December 31, 2020

Full year 2020 earnings released: EPS US$0.24 (vs US$0.002 in FY 2019)

Medtecs International Corporation Limited Announces Management Changes

Earnings beat expectations, revenue disappoints

Full year 2020 earnings released

Wan Chien Yang Appoints as General Counsel of the Medtecs International Corporation Limited, Effective 1 March 2021

Medtecs International Corporation Limited Enters into A Letter of Intent with Enimmune Co., Ltd

CEO & Executive Director recently bought S$527k worth of stock

Market bids up stock over the past week

CEO & Executive Director recently bought S$921k worth of stock

New 90-day low: S$0.93

Market bids up stock over the past week

Earnings released

New 90-day high - S$0.90

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd